Losartan Dosing in Elevated Liver Transaminases
In a male patient with elevated liver transaminases indicating mild hepatic impairment, start losartan at 25 mg once daily and titrate cautiously with close monitoring of liver function.
Starting Dose
The FDA-approved prescribing information is explicit: use a starting dose of 25 mg for patients with mild to moderate hepatic impairment 1. This reduced starting dose (half the standard 50 mg) is necessary because patients with mild-to-moderate hepatic impairment have approximately 5-fold higher plasma concentrations of losartan and 1.7-fold higher concentrations of its active metabolite compared to healthy volunteers 1. The oral bioavailability is approximately doubled, and total plasma clearance is reduced by about 50% in hepatic impairment 1.
Key Considerations Before Starting
- Severity assessment: The 25 mg starting dose applies to mild-to-moderate hepatic impairment. Losartan has not been studied in severe hepatic impairment and should be avoided in that population 1
- Baseline monitoring: Document baseline transaminase levels (ALT/AST), alkaline phosphatase, and bilirubin before initiating therapy
- Rule out other causes: Ensure elevated transaminases are not due to acute hepatitis, viral hepatitis, autoimmune disease, or other hepatotoxic medications 2
Titration Strategy
After starting at 25 mg daily:
- Monitor liver enzymes closely during the initial weeks of therapy, particularly if transaminases are 2-5 times the upper limit of normal
- Titrate gradually only if blood pressure control is inadequate and liver function remains stable or improves
- The maximum recommended daily dose is 100 mg, but this should be approached cautiously in hepatic impairment
- Do not titrate if transaminases worsen or if patient develops symptoms of hepatotoxicity (jaundice, right upper quadrant pain, fatigue, dark urine)
Critical Monitoring Parameters
If baseline AST/ALT is 2-5 times normal (mild elevation):
- Monitor liver function weekly for two weeks, then every two weeks until stable or normalized 2
- Continue monitoring monthly for the first 3 months after any dose adjustment
If AST/ALT rises to ≥5 times normal or bilirubin rises:
- Discontinue losartan immediately 2
- Switch to an alternative antihypertensive class (e.g., calcium channel blocker like amlodipine) 3
Important Caveats
Losartan-induced hepatotoxicity is rare but can be severe: Recent case reports document marked hepatotoxicity, sub-fulminant hepatitis, and even acute liver failure requiring transplantation with losartan use 3, 4, 5. While uncommon, these cases emphasize the need for vigilance, particularly in patients with pre-existing liver enzyme elevation.
Drug interactions: Avoid strong/moderate CYP3A4 inhibitors and monitor closely with weak CYP3A4 inhibitors (including atorvastatin), as these can alter losartan metabolism 1. Fluconazole increases losartan AUC by 70% while decreasing active metabolite formation 1.
Volume status matters: If the patient is also volume depleted (common in hypertensive patients on diuretics), additional dose reduction or closer monitoring may be warranted 1.
When NOT to Use Losartan
- Severe hepatic impairment (not studied, avoid use) 1
- Active liver disease with unexplained persistent abnormal liver function tests
- Pregnancy (all trimesters) 1
- If transaminases are rising despite treatment or if patient develops symptoms of hepatic decompensation
Bottom line: The reduced 25 mg starting dose in hepatic impairment is mandatory per FDA labeling, not optional. This population has significantly altered pharmacokinetics that necessitate dose adjustment. Close monitoring allows early detection of the rare but potentially severe hepatotoxicity that can occur with losartan therapy.